Literature DB >> 688243

Adriamycin and mitomycin C: possible synergistic cardiotoxicity.

A U Buzdar, S S Legha, C K Tashima, G N Hortobagyi, H Y Yap, A N Krutchik, M A Luna, G R Blumenschein.   

Abstract

Ninety-one patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P = 0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 688243

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  12 in total

1.  Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.

Authors:  F Villani; R Comazzi; G Lacaita; A Guindani; V Genitoni; A Volonterio; M C Brambilla
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

2.  Antitumor chemotherapy after fluorouracil angina.

Authors:  G Beretta; R Labianca; F Montinari; G Luporini
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

Review 3.  The role of antioxidants in the era of cardio‑oncology.

Authors:  Duncan T Vincent; Yasmine F Ibrahim; Michael Graham Espey; Yuichiro J Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2013-12       Impact factor: 3.333

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

5.  A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer.

Authors:  F A Holmes; L Esparza; H Y Yap; A U Buzdar; G R Blumenschein; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Phase I trial of FK973: description of a delayed vascular leak syndrome.

Authors:  R Pazdur; D H Ho; K Daugherty; W T Bradner; I H Krakoff; M N Raber
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

7.  A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.

Authors:  J Verweij; A J Funke-Küpper; G J Teule; H M Pinedo
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

8.  Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro.

Authors:  R T Dorr; N G Shipp; J D Liddil; B S Iyengar; K R Kunz; W A Remers
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

Review 10.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.